Successful Desensitization Protocol in an Infant Following Anaphylaxis Secondary to Recombinant Factor VIIa

被引:2
|
作者
Ulusoy Severcan, Ezgi [1 ]
Cigerci Gunaydin, Nursen [2 ]
Hekimci Ozdemir, Hamiyet [3 ]
Gulen, Figen [4 ]
Kavakli, Kaan [5 ]
Tanac, Remziye [6 ]
Demir, Esen [6 ]
机构
[1] Hlth Sci Univ, Dr Sami Ulus Matern & Children Training & Res Hos, Dept Pediat Allergy & Immunol, Ankara, Turkey
[2] Namik Kemal Univ, Div Pediat Allergy & Immunol, Dept Pediat, Fac Med, TR-59100 Tekirdag, Turkey
[3] Ege Univ, Fac Med, Dept Pediat, Div Pediat Oncol & Hematol, Izmir, Turkey
[4] Ege Univ, Fac Med, Div Pediat Allergy & Immunol, Izmir, Turkey
[5] Ege Univ, Fac Med, Dept Pediat, Div Hematol, Izmir, Turkey
[6] Ege Univ, Fac Med, Pediat Allergy & Immunol, Izmir, Turkey
关键词
desensitization; drug allergy; factor VIIa; ACTIVATED FACTOR-VII; FACTOR-IX DEFICIENCY; HYPERSENSITIVITY REACTIONS; RAPID DESENSITIZATION; DRUG HYPERSENSITIVITY; SAFETY; CHEMOTHERAPY; INHIBITORS; DIAGNOSIS; ALLERGY;
D O I
10.1089/ped.2019.1130
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background:Recombinant factor VIIa (rFVIIa) is a highly purified recombinant protein. It is approved for the treatment and prevention of bleeding episodes associated with congenital factor VII deficiency, congenital hemophilia with inhibitors, and Glanzmann's thrombasthenia. The most commonly reported adverse events are thrombolytic in nature. In this report, we present a successful desensitization protocol administered to an infant with a history of anaphylaxis to rFVIIa. Case:A male infant with a history of gingival bleeding at the age of 6 months was diagnosed with factor VII deficiency with a factor VII level of 1%. His sister also had diagnosis of factor VII deficiency. Our patient was hospitalized at 10 months of age with generalized petechiae and bloody stools. Twenty minutes after administration of rFVIIa, he developed anaphylaxis that responded to epinephrine and supportive care. Subsequently he was evaluated at the allergy clinic, where a skin prick test with rFVIIa was negative. However, the intradermal skin test, applied with 1/1,000 (1 mu g/1 mL, 0.1 mL) dilution of rFVIIa, showed induration of 8 mm (positive reaction). Because there is no alternative treatment for factor VII deficiency, we developed a successful 13-step desensitization protocol with rFVIIa (NovoSeven(R)). Desensitization was performed an additional 2 times using the same protocol, one of which was for a head injury and the other for a swollen knee since the period between the doses was similar to 3 months. Conclusion:Allergic reactions, such as anaphylaxis can occur without prior exposure. This can be due to the high molecular weight and structural property of the biological agent. In this report, we present an effective desensitization protocol for an infant with a history of anaphylaxis to rFVIIa. Desensitization protocols in this age group should be carried out in a medical facility and with specialized staff and equipment prepared to care for anaphylaxis.
引用
收藏
页码:159 / 162
页数:4
相关论文
共 50 条
  • [1] Successful desensitisation protocol following anaphylaxis secondary to recombinant factor VIIa
    Oussaid, A. Mohand
    Boukhedouma, N.
    Sekfali, L.
    Benhalla, N. K.
    Bouterfas, N.
    Bouferoua, F.
    [J]. HAEMOPHILIA, 2024, 30 : 140 - 140
  • [2] A desensitization case of recombinant factor VIIa
    Demir, E.
    Ulusoy, E.
    Gunaydin, Cigerci N.
    Tanac, R.
    Ozdemir, Hekimci H.
    Kavakli, K.
    Gulen, F.
    [J]. ALLERGY, 2017, 72 : 635 - 635
  • [3] A successful shortening of desensitization protocol in a patient with cetuximab anaphylaxis
    Seo, Jang Ho
    Jung, Jiung
    Yoon, Jeong Eun
    Kim, Hyun Hwa
    Kim, Hyun Ji
    Lee, Suh Young
    Kang, Hye-Ryun
    [J]. ALLERGY ASTHMA & RESPIRATORY DISEASE, 2022, 10 (03): : 181 - 185
  • [4] Refractory bleeding following major surgery of a giant sacrococcygeal teratoma in a premature infant: successful use of recombinant factor VIIa
    Monika Girisch
    Ralf Rauch
    Roman Carbon
    Thomas Habash
    Michael Hofbeck
    [J]. European Journal of Pediatrics, 2004, 163 : 118 - 119
  • [5] Successful use of recombinant factor VIIa in a preterm infant with life-threatening haematuria
    Faust, Kirstin
    Troeger, Birthe
    Kahl, Fritz
    Schumacher, Marius
    Goepel, Wolfgang
    Haertel, Christoph
    [J]. BLOOD COAGULATION & FIBRINOLYSIS, 2009, 20 (07) : 601 - 604
  • [6] Refractory bleeding following major surgery of a giant sacrococcygeal teratoma in a premature infant: successful use of recombinant factor VIIa
    Girisch, M
    Rauch, R
    Carbon, R
    Habash, T
    Hofbeck, M
    [J]. EUROPEAN JOURNAL OF PEDIATRICS, 2004, 163 (02) : 118 - 119
  • [7] Successful use of recombinant factor VIIa in a patient with inhibitor secondary to severe factor XI deficiency
    Lawler, P
    White, B
    Pye, S
    Hermans, C
    Riddell, A
    Costello, C
    Brown, S
    Lee, CA
    [J]. HAEMOPHILIA, 2002, 8 (02) : 145 - 148
  • [8] Successful treatment of intractable hemorrhage with recombinant factor VIIa during cranial vault reconstruction in an infant
    Stricker, Paul A.
    Petersen, Christian
    Fiadjoe, John E.
    Mccloskey, John J.
    [J]. PEDIATRIC ANESTHESIA, 2009, 19 (08) : 806 - 807
  • [9] Successful reversal of deleterious coagulopathy by recombinant factor VIIa
    Haas, T
    Innerhofer, P
    Kühbacher, G
    Fries, D
    [J]. ANESTHESIA AND ANALGESIA, 2005, 100 (01): : 54 - 58
  • [10] Successful treatment of severe gastrointestinal bleeding secondary to Crohn disease bath recombinant factor VIIa
    Girona, Eva
    Borras-Blasco, Joaquin
    Conesa-Garcia, Venancio
    Navarro-Ruiz, Andres
    Solis, Javier
    Fe Garcia-Sepulcre, Mariana
    Oliver-Garcia, Israel
    [J]. SOUTHERN MEDICAL JOURNAL, 2007, 100 (06) : 601 - 604